From Omega Diagnostics Group PLC
Omega Diagnostics Group PLC is focused on selling a wide range of specialist products, primarily in the immunoassay, in-vitro diagnostics (IVD) market within three segments: Allergy, Food Intolerance and Global Health.
Originally founded as Omega Diagnostics Ltd in Scotland, the Company's global reputation stems from beginnings as a manufacturer of tests for a range of infectious diseases such as syphilis, tuberculosis, dengue fever, chagas disease and malaria.
The Company's product range was extended following the acquisition of Genesis Diagnostics Ltd and Cambridge Nutritional Sciences Ltd in September 2007 giving customers access to tests for the fast growing area of food intolerance testing. In 2010, Omega acquired the IVD division of allergy and specific immunotherapy specialist Allergopharma Joachim Ganzer KG, giving further access to a range of allergy tests for over 600 allergens.
In 2012, Omega announced that it had entered into an agreement providing worldwide exclusive access to a point of care (POC) test for CD4 developed by Burnet Institute in Melbourne, Australia. Testing for the number of CD4 T+ cells is a vital component for the management and care of people suffering from HIV and is required to determine when HIV patients should commence antiretroviral treatment (ART). In 2018, a restructure of operations was carried out whereby the four UK companies were amalgamated into one entity, Omega Diagnostics Ltd. Further to this, in 2018 the Company disposed of its infectious disease business, with the exception of VISITECT CD4, to Novacyt SA, an international specialist in clinical diagnostics.